{"id":64869,"date":"2026-05-09T21:05:28","date_gmt":"2026-05-09T13:05:28","guid":{"rendered":"https:\/\/flcube.com\/?p=64869"},"modified":"2026-05-09T21:05:29","modified_gmt":"2026-05-09T13:05:29","slug":"bristol-myers-squibb-reports-11-49-billion-q1-revenue-with-strong-growth-portfolio-performance","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64869","title":{"rendered":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance"},"content":{"rendered":"\n<p><strong>Bristol-Myers Squibb<\/strong> (BMS, <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>) reported <strong>first-quarter 2026 revenue of $11.489 billion<\/strong>, representing a <strong>1% year-over-year (YOY) increase<\/strong>, according to its financial results released this week. The company&#8217;s <strong>Growth Portfolio<\/strong> delivered <strong>$6.2 billion in revenue<\/strong>, up <strong>9% YOY<\/strong>, driven primarily by strong performances from <strong>Camzyos<\/strong>, <strong>Breyanzi<\/strong>, and <strong>Reblozyl<\/strong>, while the <strong>Legacy Portfolio<\/strong> declined <strong>8% YOY to $5.3 billion<\/strong> amid ongoing generic competition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q1 2026<\/th><th>YOY Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>$11.489 billion<\/td><td>+1%<\/td><\/tr><tr><td><strong>Growth Portfolio<\/strong><\/td><td>$6.2 billion<\/td><td>+9%<\/td><\/tr><tr><td><strong>Legacy Portfolio<\/strong><\/td><td>$5.3 billion<\/td><td>-8%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-performance-highlights\">Key Product Performance Highlights<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-oncology-franchise\">Oncology Franchise<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Opdivo<\/strong> (nivolumab): $2.146 billion (-8% YOY)<\/li>\n\n\n\n<li><strong>Yervoy<\/strong> (ipilimumab): $651 million (+2% YOY)<\/li>\n\n\n\n<li><strong>Breyanzi<\/strong> (lisocabtagene maraleucel): $410 million (+53% YOY)<\/li>\n\n\n\n<li><strong>Reblozyl<\/strong> (luspatercept): $555 million (+15% YOY)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cardiovascular-amp-other\">Cardiovascular &amp; Other<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eliquis<\/strong> (apixaban): $4.137 billion (+13% YOY)<\/li>\n\n\n\n<li><strong>Camzyos<\/strong> (mavacamten): $314 million (+4% YOY)<\/li>\n<\/ul>\n\n\n\n<p>The <strong>13% growth in Eliquis sales<\/strong> was partially offset by continued generic erosion affecting other Legacy Portfolio products, resulting in the overall portfolio decline.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-outlook-amp-guidance\">Strategic Outlook &amp; Guidance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Full-Year 2026 Revenue Guidance:<\/strong> $46.0\u201347.5 billion<\/li>\n\n\n\n<li><strong>Global Apixaban Sales Growth Expectation:<\/strong> 10%\u201315%<\/li>\n\n\n\n<li><strong>Growth Portfolio Momentum:<\/strong> Continued strong uptake of cell therapy (Breyanzi) and cardiovascular innovation (Camzyos)<\/li>\n\n\n\n<li><strong>Legacy Portfolio Challenges:<\/strong> Ongoing patent expirations and generic competition expected to persist throughout 2026<\/li>\n<\/ul>\n\n\n\n<p>The company&#8217;s strategic pivot toward its Growth Portfolio is yielding positive results, with cell therapy and targeted oncology assets demonstrating robust commercial adoption. Breyanzi&#8217;s 53% growth reflects increasing market penetration in large B-cell lymphoma, while Reblozyl continues to expand in myelodysplastic syndromes and beta thalassemia indications.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding financial performance, product sales, and business strategy. Actual results may differ due to risks including competitive dynamics, regulatory changes, market conditions, and generic competition.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/BMY-Q1-2026-Earnings-Press-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of BMY-Q1-2026-Earnings-Press-Release.\"><\/object><a id=\"wp-block-file--media-7f081ae1-7328-4418-ab72-27f5d2c4d901\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/BMY-Q1-2026-Earnings-Press-Release.pdf\">BMY-Q1-2026-Earnings-Press-Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/BMY-Q1-2026-Earnings-Press-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-7f081ae1-7328-4418-ab72-27f5d2c4d901\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1%&#8230;<\/p>\n","protected":false},"author":1,"featured_media":64871,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[429,428,27,849],"class_list":["post-64869","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-bms","tag-bristol-myers-squibb","tag-finanical-reports","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company&#039;s Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64869\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company&#039;s Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64869\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-09T13:05:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-09T13:05:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance\",\"datePublished\":\"2026-05-09T13:05:28+00:00\",\"dateModified\":\"2026-05-09T13:05:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869\"},\"wordCount\":270,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0901-1.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"Finanical Reports\",\"NYSE: BMY\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64869#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64869\",\"name\":\"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0901-1.webp\",\"datePublished\":\"2026-05-09T13:05:28+00:00\",\"dateModified\":\"2026-05-09T13:05:29+00:00\",\"description\":\"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company's Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64869\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0901-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/0901-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64869#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company's Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64869","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance","og_description":"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company's Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.","og_url":"https:\/\/flcube.com\/?p=64869","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-09T13:05:28+00:00","article_modified_time":"2026-05-09T13:05:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64869#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64869"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance","datePublished":"2026-05-09T13:05:28+00:00","dateModified":"2026-05-09T13:05:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64869"},"wordCount":270,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=64869#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","keywords":["BMS","Bristol-Myers Squibb","Finanical Reports","NYSE: BMY"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64869#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64869","url":"https:\/\/flcube.com\/?p=64869","name":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=64869#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=64869#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","datePublished":"2026-05-09T13:05:28+00:00","dateModified":"2026-05-09T13:05:29+00:00","description":"Bristol-Myers Squibb (BMS, NYSE: BMY) reported first-quarter 2026 revenue of $11.489 billion, representing a 1% year-over-year (YOY) increase, according to its financial results released this week. The company's Growth Portfolio delivered $6.2 billion in revenue, up 9% YOY, driven primarily by strong performances from Camzyos, Breyanzi, and Reblozyl, while the Legacy Portfolio declined 8% YOY to $5.3 billion amid ongoing generic competition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64869#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64869"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=64869#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","width":1080,"height":608,"caption":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64869#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb Reports $11.49 Billion Q1 Revenue with Strong Growth Portfolio Performance"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/0901-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64869"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64869\/revisions"}],"predecessor-version":[{"id":64872,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64869\/revisions\/64872"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/64871"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}